Various pharmacological approaches to potentiate the therapeutic actions of levodopa and reduce side-effects are reviewed.
THERE is severe depletion of dopamine in the brain of Parkinsonian patients (Hornykiewicz, 1966) . Levodopa is now a well established treatment for Parkinsonism but its therapeutic action is often associated with prominent unwanted side-effects. Most of the side-effects are dose-dependent.
We review here the various theoretical and practical ways of modifying levodopa treatment in order to minimize side-effects without reduction in therapeutic efficacy.
Anticholinergic drugs
Before the advent of levodopa therapy for Parkinsonism, anticholinergic drugs were the mainstay of treatment and invariably patients were on one or more of these drugs. It seemed logical to withdraw these when levodopa came to be the effective treatment. Hughes et al. (1971) investigated gradual and sudden withdrawal of anticholinergic drugs in a group of patients receiving a stable dose of levodopa for Parkinsonism. They found that only eleven out of thirty-four patients were able to tolerate either gradual or sudden withdrawal for more than eight weeks. They suggest that synergism seems to exist between anticholinergic drugs and levodopa and this may be due either to inhibition of dopamine inactivation or a primary central anticholinergic effect. Conversely, it would appear from their results that the introduction of anticholinergic drugs in patients treated initially with levodopa is likely to produce additional benefit.
Amantadine
Amantadine hydrochloride, a drug recently introduced for Parkinsonism (Schwab et al., 1969) has been found to release dopamine and other catecholamines from neuronal storage sites in dogs (Grelak et al., 1970) . In mice, the actions of levodopa are potentiated by amantadine (Svensson & Stromberg, 1970) . The reported efficacy of amantadine in Parkinsonism may be due to the release of dopamine, but reports of synergism with levodopa have been conflicting (Godwin-Austen et al., 1970; Hunter et al., 1970a; Parkes et al., 1971; Sacks, Schwartz & Messeloff, 1971 (Braham, 1970) . Ericsson (1971) has conducted a clinical trial with N-butylgallate (GPA 1714), a drug which inhibits COMT in vivo and in vitro. He noted alleviation of Parkinsonian features and was able to reduce the dose of levodopa. There was a reduction of nausea, vomiting and involuntary movements.
Inhibition of dopamine beta hydroxylase
Theoretically, another way to increase the concentration of cerebral dopamine is to block its conversion to noradrenaline by inhibiting the enzyme dopamine beta hydroxylase. In animals disulfiram, a beta hydroxylase inhibitor, was found to increase the concentration of dopamine in the caudate nucleus, hypothalamus and brain stem with a corresponding reduction of noradrenaline (Goldstein & Nakajima, 1967) . Clinically, however, Braham (1970) found no improvement after addition of disulfiram to levodopa therapy.
Fusaric acid, another inhibitor of dopamine beta hydroxylase, has also been investigated in Parkinsonism. When administered in combination with levodopa, a better therapeutic result was achieved than that obtainable with either drug (Hidaka, 1971 ). Mena, Court & Cotzias (1971) found that fusaric acid caused neither improvement nor worsening of signs or symptoms of Parkinsonism but they reported that this drug alleviated the involuntary movements produced by levodopa. They suggested that noradrenaline formed from dopamine causes the involuntary movements which occur with levodopa therapy.
Alkalinization of gastric contents
In six patients who had failed to respond to high doses of levodopa, Rivera-Calimlim et al. (1970) found increased gastric acidity and prolonged emptying time. Fractionation of the gastric juice showed significant quantities of levodopa metabolites, suggesting destruction of administered levodopa in the stomach. Addition of an antacid (magnesium and aluminium hydroxide) resulted in increased levodopa levels in the blood and clinical improvement. An antacid given half an hour before the dose of levodopa may thus prove useful in some patients.
Dopamine agonists
Apomorphine, a dopaminergic stimulant, is therapeutically active in Parkinsonism and augments the effects of levodopa. However, it causes severe nausea; it has to be injected; and its effects are only brief (Duby, Dahl & Cotzias, 1971 ).
Monoamine oxidase inhibitors
These drugs potentiate the actions of levodopa by blocking the breakdown of dopamine and noradrenaline. Unfortunately, toxic effects are augmented in addition to the therapeutic action (Barbeau, 1961 (Barbeau, , 1962 . Dangerous hypertension has been reported following administration of levodopa with monoamine oxidase inhibitors (Hunter et al., 1970b) .
Extracerebral decarboxylase inhibitors
The most satisfactory method, at present, to potentiate the action of levodopa, is selective blockade of extracerebral decarboxylase as first suggested by Bartholini et al. (1967) . Levodopa is avidly decarboxylated to dopamine by the enzyme L-aromatic amino acid decarboxylase in the blood and tissues. Dopamine formed outside the central nervous system does not readily cross the blood-brain barrier. Because L-aromatic amino acid decarboxylase is so widespread, large doses of levodopa must be given to generate a therapeutic blood level. The large intake of levodopa may produce unwanted effects by peripheral adrenergic activity. Drugs are available which inhibit L-aromatic amino acid decarboxylase but are unable to penetrate the blood-brain barrier. The use of extracerebral decarboxylase inhibitors prevents the conversion of levodopa to dopamine in the gut, blood and peripheral tissues, thus enabling a larger proportion of the administered levodopa to cross the blood-brain barrier and there be converted to dopamine.
Initial reports with extracerebral decarboxylase inhibitors, such as L-alpha methyldopahydrazine and seryltrihydroxybenzylhydrazine, are encouraging (Cotzias, Papavasiliou & Gellene, 1969; Bartholini et al., 1969; Barbeau, 1969; Siegfried et al., 1969; Calne et al., 1971) . We now report six patients with idiopathic Parkinsonism, treated with lower doses ofL-alpha methyldopahydrazine than have previously been employed.
The patients were treated in a double-blind, randomized cross-over comparison of levodopa with and without L-alpha methyldopahydrazine. Regimen A comprised L-alpha methyldopahydrazine, 100 mg a day in four divided doses, plus maximum tolerated dosage of levodopa. Regimen B comprised levodopa alone in maximum tolerated dosage. Each drug regimen was administered over a period of 6 weeks.
Clinical features were evaluated according to an arbitrary scoring protocol from 0 (normal) to 4 (severe disability). The results are summarized in Table 1 . The maximum tolerated doses of levodopa are shown in Table 2 . The effects of treatment on nausea ( Fig. 1 ) and blood pressure (Fig. 2) are shown by linked scattergrams.
There were no obvious differences in the therapeutic responses on the two regimens, but nausea was less troublesome when patients were receiving L- The overall results are very similar to those obtained with three times the dose of L-alpha methyldopahydrazine (Calne et al., 1971) .
